

Protalix BioTherapeutics, Inc.  
Form 8-K  
March 11, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 11, 2009

**Protalix BioTherapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

Florida  
(State or other jurisdiction of  
incorporation)

000-27836  
(Commission File Number)

65-0643773  
(IRS Employer Identification No.)

**2 Snunit Street  
Science Park  
POB 455  
Carmiel, Israel 20100**

(Address of principal executive offices) (Zip Code)  
(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On March 11, 2009, Protalix BioTherapeutics, Inc. (the Company) issued a press release announcing that the Office of the Chief Scientist (OCS) of Israel's Ministry of Industry, Trade and Labor has awarded a grant of over \$6 million to the Company for calendar year 2009. The OCS awarded the grant to the Company to promote the advancement of the Company's clinical and preclinical drug development programs. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated March 11, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: March 11, 2009

By: /s/ David Aviezer  
Name: David Aviezer, Ph.D.  
Title: President and Chief Executive  
Officer